Suppr超能文献

美国心脏协会 PREVENT 方程的制定与验证。

Development and Validation of the American Heart Association's PREVENT Equations.

机构信息

Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL (S.S.K.).

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (K.M., Y.S., S.H.B., J.C.).

出版信息

Circulation. 2024 Feb 6;149(6):430-449. doi: 10.1161/CIRCULATIONAHA.123.067626. Epub 2023 Nov 10.

Abstract

BACKGROUND

Multivariable equations are recommended by primary prevention guidelines to assess absolute risk of cardiovascular disease (CVD). However, current equations have several limitations. Therefore, we developed and validated the American Heart Association Predicting Risk of CVD EVENTs (PREVENT) equations among US adults 30 to 79 years of age without known CVD.

METHODS

The derivation sample included individual-level participant data from 25 data sets (N=3 281 919) between 1992 and 2017. The primary outcome was CVD (atherosclerotic CVD and heart failure). Predictors included traditional risk factors (smoking status, systolic blood pressure, cholesterol, antihypertensive or statin use, and diabetes) and estimated glomerular filtration rate. Models were sex-specific, race-free, developed on the age scale, and adjusted for competing risk of non-CVD death. Analyses were conducted in each data set and meta-analyzed. Discrimination was assessed using the Harrell C-statistic. Calibration was calculated as the slope of the observed versus predicted risk by decile. Additional equations to predict each CVD subtype (atherosclerotic CVD and heart failure) and include optional predictors (urine albumin-to-creatinine ratio and hemoglobin A1c), and social deprivation index were also developed. External validation was performed in 3 330 085 participants from 21 additional data sets.

RESULTS

Among 6 612 004 adults included, mean±SD age was 53±12 years, and 56% were women. Over a mean±SD follow-up of 4.8±3.1 years, there were 211 515 incident total CVD events. The median C-statistics in external validation for CVD were 0.794 (interquartile interval, 0.763-0.809) in female and 0.757 (0.727-0.778) in male participants. The calibration slopes were 1.03 (interquartile interval, 0.81-1.16) and 0.94 (0.81-1.13) among female and male participants, respectively. Similar estimates for discrimination and calibration were observed for atherosclerotic CVD- and heart failure-specific models. The improvement in discrimination was small but statistically significant when urine albumin-to-creatinine ratio, hemoglobin A1c, and social deprivation index were added together to the base model to total CVD (ΔC-statistic [interquartile interval] 0.004 [0.004-0.005] and 0.005 [0.004-0.007] among female and male participants, respectively). Calibration improved significantly when the urine albumin-to-creatinine ratio was added to the base model among those with marked albuminuria (>300 mg/g; 1.05 [0.84-1.20] versus 1.39 [1.14-1.65]; =0.01).

CONCLUSIONS

PREVENT equations accurately and precisely predicted risk for incident CVD and CVD subtypes in a large, diverse, and contemporary sample of US adults by using routinely available clinical variables.

摘要

背景

多变量方程被初级预防指南推荐用于评估心血管疾病(CVD)的绝对风险。然而,目前的方程存在几个局限性。因此,我们在美国 30 至 79 岁无已知 CVD 的成年人中开发并验证了美国心脏协会预测 CVD 事件风险(PREVENT)方程。

方法

推导样本包括 1992 年至 2017 年 25 个数据集的个体水平参与者数据(N=3281919)。主要结局是 CVD(动脉粥样硬化性 CVD 和心力衰竭)。预测因素包括传统危险因素(吸烟状况、收缩压、胆固醇、降压药或他汀类药物使用和糖尿病)和估算肾小球滤过率。模型是性别特异性的、无种族的、按年龄尺度开发的,并调整了非 CVD 死亡的竞争风险。在每个数据集进行分析,并进行荟萃分析。使用 Harrell C 统计量评估区分度。校准通过按十分位数计算观察到的与预测风险的斜率来计算。还开发了预测每个 CVD 亚型(动脉粥样硬化性 CVD 和心力衰竭)的附加方程,并包括可选预测因子(尿白蛋白/肌酐比和血红蛋白 A1c)和社会剥夺指数。在来自 21 个额外数据集的 3330085 名参与者中进行了外部验证。

结果

在纳入的 6612046 名成年人中,平均年龄±标准差为 53±12 岁,56%为女性。平均随访 4.8±3.1 年后,共发生 211515 例总 CVD 事件。CVD 的外部验证的中位数 C 统计量在女性中为 0.794(四分位间距,0.763-0.809),在男性中为 0.757(0.727-0.778)。在女性和男性参与者中,校准斜率分别为 1.03(四分位间距,0.81-1.16)和 0.94(0.81-1.13)。对动脉粥样硬化性 CVD 和心力衰竭特定模型的区分度和校准度也观察到了类似的估计值。当将尿白蛋白/肌酐比、血红蛋白 A1c 和社会剥夺指数添加到基础模型中以计算总 CVD 时,区分度的提高虽小但具有统计学意义(ΔC 统计量[四分位间距]:女性为 0.004[0.004-0.005],男性为 0.005[0.004-0.007])。当在白蛋白尿显著的患者中(>300mg/g)将尿白蛋白/肌酐比添加到基础模型中时,校准得到显著改善(1.05[0.84-1.20]比 1.39[1.14-1.65];=0.01)。

结论

PREVENT 方程使用常规临床变量在一个大型、多样化和现代的美国成年人样本中准确且精确地预测了 CVD 和 CVD 亚型的发病风险。

相似文献

1
Development and Validation of the American Heart Association's PREVENT Equations.
Circulation. 2024 Feb 6;149(6):430-449. doi: 10.1161/CIRCULATIONAHA.123.067626. Epub 2023 Nov 10.
2
Cardiovascular Disease Risk Estimates in the US CKD Population Using the PREVENT Equation.
Am J Kidney Dis. 2025 Mar 5. doi: 10.1053/j.ajkd.2025.01.012.
5
External Validation of the American Heart Association PREVENT Cardiovascular Disease Risk Equations.
JAMA Netw Open. 2024 Oct 1;7(10):e2438311. doi: 10.1001/jamanetworkopen.2024.38311.
6
Effects of a gluten-reduced or gluten-free diet for the primary prevention of cardiovascular disease.
Cochrane Database Syst Rev. 2022 Feb 24;2(2):CD013556. doi: 10.1002/14651858.CD013556.pub2.
7
Smoking cessation for secondary prevention of cardiovascular disease.
Cochrane Database Syst Rev. 2022 Aug 8;8(8):CD014936. doi: 10.1002/14651858.CD014936.pub2.
8
Dietary Approaches to Stop Hypertension (DASH) for the primary and secondary prevention of cardiovascular diseases.
Cochrane Database Syst Rev. 2025 May 6;5(5):CD013729. doi: 10.1002/14651858.CD013729.pub2.
10
Quality improvement strategies for diabetes care: Effects on outcomes for adults living with diabetes.
Cochrane Database Syst Rev. 2023 May 31;5(5):CD014513. doi: 10.1002/14651858.CD014513.

引用本文的文献

4
Cardiovascular contributions to dementia: Examining sex differences and female-specific factors.
Alzheimers Dement. 2025 Aug;21(8):e70610. doi: 10.1002/alz.70610.
8
Cardiovascular-kidney-metabolic syndrome: A new frontier or simple rebranding?
PLoS Med. 2025 Aug 21;22(8):e1004723. doi: 10.1371/journal.pmed.1004723. eCollection 2025 Aug.
9
Demystifying the nuances of the lipid patient: a guide for primary care providers.
Am J Prev Cardiol. 2025 Jul 26;23:101070. doi: 10.1016/j.ajpc.2025.101070. eCollection 2025 Sep.

本文引用的文献

2
Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association.
Circulation. 2023 Nov 14;148(20):1606-1635. doi: 10.1161/CIR.0000000000001184. Epub 2023 Oct 9.
4
Performance of the ACC/AHA Pooled Cohort Cardiovascular Risk Equations in Clinical Practice.
J Am Coll Cardiol. 2023 Oct 10;82(15):1499-1508. doi: 10.1016/j.jacc.2023.07.018.
6
Historical Redlining, Socioeconomic Distress, and Risk of Heart Failure Among Medicare Beneficiaries.
Circulation. 2023 Jul 18;148(3):210-219. doi: 10.1161/CIRCULATIONAHA.123.064351. Epub 2023 Jul 17.
8
Screening for Prediabetes and Diabetes: Clinical Performance and Implications for Health Equity.
Am J Prev Med. 2023 Jun;64(6):814-823. doi: 10.1016/j.amepre.2023.01.007. Epub 2023 Mar 24.
9
Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association.
Circulation. 2023 Feb 21;147(8):e93-e621. doi: 10.1161/CIR.0000000000001123. Epub 2023 Jan 25.
10
Albuminuria and Heart Failure: JACC State-of-the-Art Review.
J Am Coll Cardiol. 2023 Jan 24;81(3):270-282. doi: 10.1016/j.jacc.2022.10.028.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验